Log in to save to my catalogue

Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study

Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_87a27195de9d45879814549aca29d5ee

Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study

About this item

Full title

Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study

Publisher

England: BMJ Publishing Group Ltd

Journal title

Journal for immunotherapy of cancer, 2023-07, Vol.11 (7), p.e007056

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

BackgroundThere has been no prospective trial for treatment of immune-related pneumonitis (irP) occurred after immune checkpoint inhibitors (ICIs).MethodsIn this single-arm phase II study, patients with cancer with grade ≥2 irP received oral prednisolone (1 mg/kg/day), tapered over 6 weeks. The primary endpoint was a pneumonitis control rate at 6 w...

Alternative Titles

Full title

Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_87a27195de9d45879814549aca29d5ee

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_87a27195de9d45879814549aca29d5ee

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1136/jitc-2023-007056

How to access this item